Phase 2 Local Clinical Trials
295 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 295 trials
Recruiting
Phase 2
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
Locally Advanced Cutaneous Squamous Cell Carcinoma
Philogen S.p.A.92 enrolled19 locationsNCT07228442
Recruiting
Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
Locally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
National Cancer Institute (NCI)115 enrolled1 locationNCT03907475
Recruiting
Phase 2
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Metastatic Non-small Cell Lung Cancer (NSCLC)Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb160 enrolled71 locationsNCT07680764
Recruiting
Phase 2Phase 3
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Metastatic OsteosarcomaHigh Grade OsteosarcomaLocalized Osteosarcoma+1 more
National Cancer Institute (NCI)1,122 enrolled202 locationsNCT05691478
Recruiting
Phase 1Phase 2
Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung CancerLocally Advanced Non-Small Cell Lung CancerUnresectable Stage III NSCLC
Shanghai Chest Hospital108 enrolled1 locationNCT07632365
Recruiting
Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled483 locationsNCT05564377
Recruiting
Phase 1Phase 2
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Colorectal, CancerProstate CancerCancer+12 more
Parabilis Medicines, Inc.619 enrolled33 locationsNCT05919264
Recruiting
Phase 1Phase 2
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Stage III Pancreatic Cancer AJCC v8Locally Advanced Pancreatic Adenocarcinoma
National Cancer Institute (NCI)92 enrolled44 locationsNCT04172532
Recruiting
Phase 1Phase 2
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Metastatic Breast CancerLocally Advanced Breast CancerUnresectable Breast Carcinoma
BioNTech SE380 enrolled68 locationsNCT06827236
Recruiting
Phase 1Phase 2
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Locally Advanced/Metastatic Solid Tumors
Crescent Biopharma, Inc.290 enrolled25 locationsNCT07335497
Recruiting
Phase 2
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Locally Advanced Adrenal Cortical CarcinomaMetastatic Adrenal Cortical CarcinomaRecurrent Adrenal Cortical Carcinoma+3 more
National Cancer Institute (NCI)48 enrolled76 locationsNCT06900595
Recruiting
Phase 2Phase 3
PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
Prostate Cancer (Adenocarcinoma)Stereotactic Body Radiation Therapy (SBRT)Localized Prostate Cancer+2 more
Affidea Nu-med Center of Oncological DIagnostics and Therapy1,000 enrolled1 locationNCT07426055
Recruiting
Phase 2
L19IL2/TNF in Patients With Basal Cell Carcinoma
Locally Advanced Basal Cell Carcinoma
Philogen S.p.A.92 enrolled18 locationsNCT07227870
Recruiting
Phase 2
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
Locally Advanced or Metastatic Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.180 enrolled1 locationNCT06439771
Recruiting
Phase 2
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
Localized Prostate Cancer
National Cancer Institute (NCI)130 enrolled1 locationNCT05155046
Recruiting
Phase 2
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
Locally Advanced Hepatocellular CarcinomaLocally Advanced Gastric CarcinomaAdvanced Biliary Tract Carcinoma+7 more
OHSU Knight Cancer Institute66 enrolled1 locationNCT05705492
Recruiting
Phase 2
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Lung Neuroendocrine NeoplasmAdvanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine Tumor+9 more
National Cancer Institute (NCI)70 enrolled29 locationsNCT04665739
Recruiting
Phase 1Phase 2
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Locally Advanced Pancreatic CarcinomaMetastatic Pancreatic CarcinomaStage II Pancreatic Cancer AJCC v8+6 more
National Cancer Institute (NCI)49 enrolled3 locationsNCT05053971
Recruiting
Phase 1Phase 2
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung CancerAdvanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals40 enrolled7 locationsNCT07468071
Recruiting
Phase 2
SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment
HER2-positive, Unresectable, Locally Advanced or Metastatic Breast CancerSKB264Inetetamab
Fudan University48 enrolled1 locationNCT07182721